Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells

E-Pien Tan1, Yilong Li, Martin Del Castillo Velasco-Herrera

  • 1Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.

Genesis (New York, N.Y. : 2000)
|November 8, 2014
PubMed

Insights

CRISPR-Cas9 gene editing shows low off-target DNA breaks in human and mouse cells. Careful guide RNA selection minimizes unintended Cas9 cutting, ensuring predictable and safe genome editing applications.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • CRISPR-Cas9 is a powerful gene editing tool with broad applications.
  • Understanding Cas9's off-target DNA cutting is crucial for successful gene editing and screening.
  • Off-target activity must be quantified to ensure the safety and efficacy of CRISPR-Cas9 applications.

Purpose of the Study:

  • To characterize the rate of Cas9 off-target activity in typical experimental conditions.
  • To analyze Cas9 cutting efficiency at targeted and predicted off-target sites across different cell lines.
  • To determine the predictability of Cas9 off-target effects based on sequence complementarity.

Main Methods:

  • Evaluated Cas9 cutting activity of 12 guide RNAs (gRNAs) in human 293FT, human-induced pluripotent stem (hiPS), and mouse embryonic stem (ES) cells.
  • Analyzed both on-target and approximately 90 predicted off-target sites per gRNA.
  • Assessed cutting rates and DNA repair patterns, including clonal analysis in mouse ES cells.

Main Results:

  • Cas9 cutting was detected at all on-target sites and only a few off-target sites genome-wide.
  • Cutting rates and DNA repair patterns showed high correlation between the two human cell lines.
  • Biallelic Cas9 cutting was observed in mouse ES cells with low off-target activity.

Conclusions:

  • Cas9 off-target activity is generally low and predictable based on sequence identity between the gRNA and potential off-target sites.
  • Off-target activity can be minimized by selecting gRNAs with limited near-complementary off-target sites.
  • These findings support the reliable application of CRISPR-Cas9 in gene editing and screening.